Sirona Biochem Corp.

Equities

SBM

CA82967M1005

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 10:13:15 17/05/2024 pm IST			5-day change	1st Jan Change
0.06 ^CAD	0.00%		-14.29%	-50.00%

08/04	Sirona Biochem Provides Update on Anti-Aging Product	MT
04/04	Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding	CI

Sirona Biochem Corp. Announces Executive Changes

October 11, 2012 at 06:30 pm IST

Sirona Biochem Corp. announced that it has named Neil Belenkie as Chief Executive Officer. Dr. Howard Verrico will remain on as Chairman of the Board.
Neil Belenkie He is the founder of strategic management consulting company GrowthPoint Group.

Latest news about Sirona Biochem Corp.

Sirona Biochem Provides Update on Anti-Aging Product	08/04	MT
Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding	04/04	CI
Sirona Biochem Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	01/04	CI
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations	13/03	MT
Sirona Biochem Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	29/02	CI
Sirona Biochem Corp. Announces Loan in the Aggregate Principal Amount of Up to $1,000,000	29/01	CI
Sirona Biochem Initiated Private Placement	29/01	MT
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding	29/01	CI
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding	26/01	CI
Sirona Biochem Corrects Earlier Statement	24/01	MT
Sirona Biochem Provides Corporate Update	24/01	MT
Sirona Biochem Launches Cosmetics Subsidiary	15/01	MT
Sirona Biochem Corp. Introduces A Wholly-Owned Subsidiary Sirona Laboratories	15/01	CI
Sirona Biochem Initiates GlycoProteMim Trademark for Anti-Aging Molecule TFC-1326	11/12	MT
Sirona Biochem Corp. Initiates GlycoProteMim?? Trademark for Anti-Aging Molecule TFC-1326	11/12	CI
Sirona Biochem Corp. Announces the Results of Its Research Collaboration with the International Centre for Genetic Engineering and Biotechnology in Advancing Sirona's Antiviral Compound Library	29/11	CI
Sirona Biochem Announced Payment of Convertible Debenture Interests in Shares	21/23/21	MT
Sirona Biochem Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	29/23/29	CI
Sirona Biochem Provides Strategic Review Update	13/23/13	MT
Sirona Biochem Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	30/23/30	CI
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEB	28/23/28	CI
Sirona Biochem to Present Anti-Aging Technology at BIO 2023 Conference in Boston	03/23/03	MT
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326	25/23/25	CI
Sirona Biochem Raises C$1.56 Million from a Private Placement of Convertible-Debenture Units	21/23/21	MT
Sirona Biochem Corp. announced that it has received CAD 1.563 million in funding	20/23/20	CI

Chart Sirona Biochem Corp.

Duration

Period

More charts

Company Profile

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChemâs proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).

Sector

Biotechnology & Medical Research

Calendar

26/06/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SIRONA BIOCHEM CORP.	-50.00%	11.31M
MODERNA, INC.	+40.41%	50.93B
IQVIA HOLDINGS INC.	-0.44%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+13.04%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-22.19%	18.9B
BIO-TECHNE CORPORATION	+8.18%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.20%	12.17B
MEDPACE HOLDINGS, INC.	+30.63%	12.16B

Other Biotechnology & Medical Research